hong-kong

2018 Speakers

 

 

 

Dr. Amber Cai is responsible for the overall Business Operations at the Novartis R&D Center in Shanghai, China (CNIBR). She leads the core business operations, overseeing a broad set of functions including External Innovation and Business Development, Public & Government Relations, Internal/External Communications, Quality Compliance, IT and Informatics, and Scientific Operations (incl. Lab Operations, Invivo studies, Import/Export etc.). More info...

 

Guillaume Vignon is Senior Vice President Business Development at BeiGene, responsible for leading all business development activities, from search & evaluation of partnering opportunities across several therapeutic areas, and all the way through till deal closing. Guillaume was previously Vice President, Global Head Oncology and Immuno-Oncology Licensing & Business Development at Merck KGaA / EMD Serono. Throughout his career, Guillaume led the closing of complex transactions and forged several strategic partnerships in the fields of Immuno-Oncology, Oncology, Companion Diagnostic, and Antibody Discovery. More info...

 

 

 

 

Bruno Delie has more than 20 years of experience in the global pharmaceutical business. Prior to being appointed General Manager of Luye Pharma in Switzerland, he was a board member and executive VP at Ethypharm. There, he was responsible for international development and the company’s transition to a specialty pharma model. Before joining Ethypharm, Bruno Delie acquired wide-ranging experience in corporate and business development as well as international sales and marketing. More info...

 

 

Dr. Ru-Yi He received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. He received his clinical and research training at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institutes of Health (NIH) of Bethesda, Maryland. He has published more than 20 research papers and abstracts in the field of Internal Medicine and Drug Regulatory Science.  More info...

 

 

 

Nigel Sheail is Head of Mergers & Acquisitions and Business Development & Licensing since September 1st, 2017 and joined Novartis in 2015 as Head of Business Development & Licensing. He is a member of the Pharmaceutical Executive Committee and Financial Leadership Team. Prior to joining Novartis, Nigel was Head of Business Development and Licensing for Bayer Healthcare. He also served as Head of Group M&A at Roche and Head of Licensing for their Pharma division. More info...

 

 

Martin Rohrbach is Partner and the Sector Head Life Sciences at KPMG Switzerland. He has been with the firm for over 20 years. Martin's comprehensive experience spans from advising multinational pharma companies to upstream supply companies to startups and early phase development companies. Martin is internationally experienced working in different roles in various locations where KPMG is present. More info...

 

 

 

 

Matthias Leuenberger is Country President of Novartis in Switzerland. In this function he serves as Chairman of the Executive Committee of Novartis Switzerland, is responsible for the company’s political relations in Switzerland and represents Novartis in the business associations Interpharma, scienceindustries, economiesuisse and HKBB (Chamber of Trade and Commerce for Basel-Stadt and Baselland). Before joining Novartis, he spent 9 years working for Boston Consulting Group in Zurich and Tokyo. Matthias Leuenberger studied law at the University of Bern, completing his bar exam in 1993 and gaining his doctorate in 1995. He is married and has three children.


 

 

Dr. Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland, the company he started in 1999 based on collaboration with the Novartis Venture Fund, which became his first client. Since then he has been involved in over 500 valuations around the globe for investors as well as Biotech, Pharma and Medtech companies. From 2013 to 2015 Patrik built the APAC Office of Venture Valuation in Singapore. Venture Valuation runs Biotechgate, a global Life Sciences database including company/asset profiles, deal information and investors and launched its premier business partnering software HelloPartnering in 2017. More info...